Akero Therapeutics, discovered novel Efruxifermin for the treatment of nonalcoholic steatohepatitis (NASH).
Efruxifermin (EFX) also known to be AKR-001, currently being evaluated in the ongoing Phase 2b HARMONY study is the main leading candidate for NASH. EFX is a novel therapy developed to reverse fibrosis, to reduce liver fat and inflammation, increase insulin sensitivity, and improve lipoproteins.
It has the ability to treat complicated, multi-system disease state of NASH together with improvements in lipoprotein risk factors linked to cardiovascular disease, the leading cause of death in NASH patients.
Nonalcoholic steatohepatitis (NASH) is a serious liver disease approximately affecting 17 million Americans. Currently there are no approved treatments for NASH and it is the fastest growing cause of liver transplants and liver cancer in the countries like US and Europe.
NASH generally results in accumulation of fat in the liver causing stress and injury to liver cells, leading to inflammation and fibrosis, which can progress to cirrhosis, liver failure, cancer and eventually death.
US Food and Drug Administration (FDA) grants breakthrough designation for Efruxifermin for the treatment of nonalcoholic steatohepatitis (NASH).
